Biohaven Ltd. Increase (Decrease) in Other Noncurrent Liabilities
Biohaven Ltd. (BHVN) reported Increase (Decrease) in Other Noncurrent Liabilities of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2023-03-23
- Biohaven Ltd. increase (decrease) in other noncurrent liabilities for the quarter ending 2022-12-31 was -$1.56M, a 769.96% decline year-over-year.
- Biohaven Ltd. increase (decrease) in other noncurrent liabilities for the quarter ending 2021-12-31 was $233.00K.
- Biohaven Ltd. increase (decrease) in other noncurrent liabilities for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Biohaven Ltd. increase (decrease) in other noncurrent liabilities for fiscal 2021 was $1.94M, a 1.36% increase from fiscal 2020.
- Biohaven Ltd. increase (decrease) in other noncurrent liabilities for fiscal 2020 was $1.91M.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|
| 2022-12-31 | -$1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 10-K · filed 2023-03-23 | |
| 2022-09-30 | $1.56M 10-Q · filed 2022-11-09 | ||
| 2021-12-31 | $233.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $1.94M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $1.71M 10-Q · filed 2022-11-09 | ||
| 2020-12-31 | $1.91M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |